SBC Medical Group Holdings Incorporated SBC R2K
Company Overview
SBC Medical Group Holdings Incorporated, together with its subsidiaries, provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and Singapore. The company offers advertising and marketing services across social media networks; staff management services, such as recruitment and training; booking reservations for franchisee clinic customers; assistance with franchisee employee housing rentals; leasehold improvement services; and design services for clinics, medical equipment, and medical consumables procurement. It also provides loyalty program management, labor and function supporting, and management consulting services; and IT software solutions, as well as engages in franchising activities; and distributes medical equipment and devices, implants, injection materials, other medical consumables, skin care and beauty products, and cosmetic products to franchisee clinics for resale to clinic customers. In addition, the company offers surgical and non-surgical surgeries that include breast augmentation; liposuction; rejuvenation treatments, such as treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs of aging; laser skin toning and spot removal; eyes double fold surgery; rhinoplasty; treatment of osmidrosis and hyperhidrosis; hair transplants; gynecological formation treatments; laser hair removal; face line surgeries; cosmetical dental procedures; tattoo removal; lasik eye surgery; lateral canthoplasty; brow lift procedures; androgenetic alopecia treatment; and cheek sagging prevention methods. Further, it owns and operates treatment centers under the SBC brand. SBC Medical Group Holdings Incorporated was founded in 2000 and is headquartered in Irvine, California.
Why Investors Should Care
Generates a return on equity of 16.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 21.1%.
Net profit has compounded at 13.8% per year over the last five years.
Trades at a P/E of 7.7, below the sector median of 30.2.
Maintains a net profit margin of 24.1%.
Carries low leverage with a debt-to-equity ratio of 0.19.
Recent Developments
- Dec 2025 Revenue of $173.61M (-15.5% YoY); net profit $50.99M.
- Trailing 12 Months Year-on-year growth — revenue -9.0%, earnings -47.1%.
- 5-Year Trend Long-term compounding — revenue CAGR -5.3%, profit CAGR 13.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -5.29% |
| 1 Year: | -9.00% |
Compounded Profit Growth
| 5 Years: | 13.80% |
| 1 Year: | -47.10% |
Stock Price Performance
| 1 Year: | -38.40% |
| 6 Months: | -31.10% |
| 3 Months: | -29.36% |
| 1 Month: | +7.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.71 · Neutral
P/E of 7.70 is below the sector median of 30.16 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 21.1%.
- Excellent profit margin of 24.1%.
- Profit CAGR of 13.8% over 5 years.
- Generates positive free cash flow.
CONS
- Revenue declined at -5.3% CAGR over 5 years.
- Trading 45.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Industrials).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SBC SBC Medical Group Holdings Incorporated R2K | 3.08 | 7.70 | $316.77M | 0.00% | 21.13% | 16.46% | -5.29% | 13.80% |
| 2 | CAT Caterpillar Inc. SPX | 914.30 | 45.35 | $421.12B | 0.70% | 17.98% | 51.33% | 2.29% | 5.24% |
| 3 | GE GE Aerospace SPX | 360.35 | 44.65 | $375.97B | 0.53% | 11.89% | 45.43% | 16.32% | 195.89% |
| 4 | GEV GE Vernova Inc. SPXAI | 1,055.28 | 30.18 | $283.57B | 0.19% | 6.30% | 75.71% | 8.68% | - |
| 5 | RTX RTX Corporation SPX | 195.89 | 36.68 | $263.80B | 1.51% | 8.28% | 11.57% | 2.61% | 2.62% |
| 6 | BA The Boeing Company SPX | 218.12 | 85.87 | $171.94B | 0.00% | -9.01% | - | 1.67% | -3.28% |
| 7 | UNP Union Pacific Corporation SPX | 288.36 | 23.75 | $171.20B | 1.91% | 15.22% | 40.69% | 2.30% | 7.77% |
| 8 | ETN Eaton Corporation plc SPXAI | 412.86 | 39.13 | $160.31B | 1.06% | 11.53% | 20.84% | 4.73% | 10.38% |
| 9 | DE Deere & Company SPX | 589.48 | 33.40 | $159.22B | 1.11% | - | 18.35% | 3.43% | 5.10% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 47.28M | 54.81M | 53.10M | 53.08M | 47.33M | 43.36M | 43.35M | 43.06M |
| Gross Profit | - | - | - | - | 33.50M | 39.52M | 39.42M | 43.24M | 37.73M | 30.01M | 30.61M | 30.35M |
| Operating Income | -1.28K | -303.62K | -388.45K | -473.37K | 20.02M | 24.46M | 27.29M | 13.83M | 24.20M | 14.55M | 15.88M | 17.72M |
| Net Income | -1.28K | -11.42K | 613.33K | 196.79K | 8.36M | 18.76M | 18.48M | 2.83M | 21.50M | 2.46M | 12.82M | 11.31M |
| Diluted EPS | - | - | - | - | 0.09 | 0.20 | 0.20 | 0.03 | 0.21 | 0.02 | 0.12 | 0.11 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 193.54M | 205.42M | 173.61M |
| Gross Profit | 137.30M | 156.05M | 127.28M |
| Operating Income | 70.66M | 70.30M | 67.49M |
| Net Income | 39.37M | 46.61M | 50.99M |
| Diluted EPS | 0.42 | 0.48 | 0.50 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 119.94M | 258.81M | 266.08M | 380.45M |
| Total Equity | -3.36M | 142.16M | 195.11M | 248.28M |
| Cash & Equivalents | 485.56K | 103.02M | 125.04M | 163.77M |
| Long Term Debt | - | - | 6.60M | 42.83M |
| Total Liabilities | 4.59M | 115.00M | 71.06M | 117.14M |
| Current Liabilities | 566.01K | 92.45M | 61.19M | 61.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 50.67M | 20.58M | 24.67M |
| Investing Cash Flow | 1.79M | -10.10M | -20.97M |
| Financing Cash Flow | 6.14M | 22.97M | 38.29M |
| Capital Expenditure | -8.54M | -2.56M | -1.40M |
| Free Cash Flow | 42.13M | 18.02M | 23.27M |
| Share Buybacks | - | 0 | 5.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 70.9% | 76.0% | 73.3% |
| Operating Margin % | 36.5% | 34.2% | 38.9% |
| Net Margin % | 20.3% | 22.7% | 29.4% |
| ROE % | 27.7% | 23.9% | 20.5% |
| ROCE % | 42.5% | 34.3% | 21.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 0.41% | 419.64K | $1.30M |
| 2 | Geode Capital Management, LLC | 0.29% | 295.78K | $913.96K |
| 3 | Vanguard Capital Management LLC | 0.13% | 136.24K | $420.98K |
| 4 | Northern Trust Corporation | 0.09% | 91.14K | $281.62K |
| 5 | Segall Bryant & Hamill, LLC | 0.08% | 81.31K | $251.24K |
| 6 | Vanguard Portfolio Management LLC | 0.06% | 63.55K | $196.36K |
| 7 | Vanguard Fiduciary Trust Co | 0.06% | 62.47K | $193.04K |
| 8 | SBI Securities Co., Ltd. | 0.04% | 45.08K | $139.30K |
| 9 | State Street Corporation | 0.03% | 30.84K | $95.29K |
| 10 | Goldman Sachs Group Inc | 0.02% | 25.09K | $77.52K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SBC
SBC Medical Group (NASDAQ: SBC) hit on Nasdaq rules, overhauls charter and bylaws - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOeWVrdVpVLXpXQVVvTkVOX2RVTmFUTW5VbzVYVlJvTTEyaVp5Qkc0a2xaY0QzX3hQQXlQeFNiVHZkNmdRZV81SHQ0amxndnNJbmlFQjBHN2FfSVhOM2c0bTZBU3VELTNXVEVqdVBCWmNBS2IxcXZ6bXUwXzB6a2tiSEtLRk85aXRDcVNmQl…
CrowdStrike: AI-Driven Growth At Hefty Premiums And SBC Risks - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNU091cUJzbFR1M0dUdzFfLWxlYnpwdk1VcDVqbVNXeTQtQ3pYWGhtV21JRkNERWtFM2F1MTdTNS1lQ2hPMnp2ejR0bTM3YWxuSXktdU9LclRxTzg1a0FfQWZYdV84aUw5azJpMWhpT3pkMS02dkVqdERvdzFHTjJ4M1VaT2o4TUlrV1ZnUD…
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock - Business Wire
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPNUFodGYwR2dXaWxjSEdOOGpvTU1UYmtaLUx4M3IyaVoxWFNJY0RaazZhRWtETHRJU3NnY3F5aGV6NVZCa2VrTTNBanJ5RVY4QzFmN2I5YUxDQ2JXMG1oWVBtV2xNUXZHbDNuWHh1UXd3WU8wVENWM1FhdFJqaXVDSjVURTlUN3VJMHB2eU…
Stock-pay boom amplifies US economic drumbeat - Reuters
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPR29LanFSSUx5ZkQ3MnVYVUVtYmJTcXBCRDFsRDhjZ1JiYjllZ1RGM25DcWEzaGhJdmVzQVVBWXJmeGd6cE9jbnNFRGg5czVzMFh2VDNVeGd6dDhCWThYYnpVLUtud19qSVoxQVNBTjdxYXB4Y2dNWFd2clZFT0RJTjJCaXhhSVI3Ui1aRT…
SBC Medical Group stock tumbles on secondary offering pricing - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQOWU5Ny1FSEFXRjF0N2lEdjl5SnVvVjk3enFDNVEyVndTN2M2b3cwMllNbnZtWUhkWVV0WG5lZEFMRDk2bWpEOXFUeFlqajNMel9WT1V1TlJWeUZaM1AzOWRsUnBhMnJ4emtCVEM1N09XRnhQcnJDTUF0bUZoM2VWS0ppRVBkSE1kcEd6Zl…
Price to sales forward of SBC Medical Group Holdings Incorporated – NASDAQ:SBC - TradingView
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPaGc0SXB3b0tuQkJvRWRCOTdkZmhWV1YxeF9wQlMwYWxfVTk1V1p1WWlVMkhiaWgtZlFmVGN5THlQbDNheVRmdjlaNnZIUUIzOGM1bEMxY21xdzdSZmFuaFNsMkMtdDd1anRsOThvSEJYS21pTjQwRndwUTdBRnhhUWhrWXVZSXpxcVpoMX…
SBC — Frequently Asked Questions
What is the current share price of SBC Medical Group Holdings Incorporated (SBC)?
As of 2026-07-15 16:51 PDT, SBC Medical Group Holdings Incorporated (SBC) trades at $3.08 on NasdaqGM. Its 52-week range is $2.87 to $5.65.
What is the market capitalisation of SBC?
SBC Medical Group Holdings Incorporated (SBC) has a market capitalisation of $316.77M on NasdaqGM.
What is the P/E ratio of SBC?
SBC trades at a trailing price-to-earnings (P/E) ratio of 7.70. The industry average P/E is 30.16. Its price-to-book (P/B) ratio is 1.24.
What is the return on equity (ROE) of SBC?
SBC has a return on equity (ROE) of 16.46%. Its return on capital employed (ROCE) is 21.13%.
Is SBC a good stock to buy?
This page provides a data-driven analysis of SBC Medical Group Holdings Incorporated (SBC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.